{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T11:37:34Z","timestamp":1792237054079,"version":"4.4.0"},"reference-count":60,"publisher":"Japanese Society for the Study of Xenobiotics","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2013]]},"DOI":"10.2133\/dmpk.dmpk-12-rv-089","type":"journal-article","created":{"date-parts":[[2012,11,19]],"date-time":"2012-11-19T22:38:15Z","timestamp":1353364695000},"page":"38-43","source":"Crossref","is-referenced-by-count":12,"title":["Clinical Evidence of Pharmacokinetic Changes in Thalidomide Therapy"],"prefix":"10.2133","volume":"28","author":[{"given":"Katsunori","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Matsuzawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Ohmori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamihide","family":"Matsunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"900","reference":[{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0005","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s002280100320","article-title":"Clinical pharmacology of thalidomide","volume":"57","author":"Eriksson","year":"2001","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0010","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0015","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1046\/j.1365-2141.2000.01983.x","article-title":"Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma","volume":"109","author":"Juliusson","year":"2000","journal-title":"Br. J. Haematol."},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0020","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1517\/13543784.7.12.2043","article-title":"Thalidomide revisited: pharmacology and clinical applications","volume":"7","author":"Calabrese","year":"1998","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0025","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3816\/CLM.2003.n.005","article-title":"Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis","volume":"3","author":"Seldin","year":"2003","journal-title":"Clin. Lymphoma"},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0030","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1182\/blood-2004-08-3231","article-title":"The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL)","volume":"105","author":"Palladini","year":"2005","journal-title":"Blood"},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0035","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1586\/14737140.1.1.20","article-title":"Thalidomide in the treatment of multiple myeloma","volume":"1","author":"Rajkumar","year":"2001","journal-title":"Expert Rev. Anticancer Ther"},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0040","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0093-7754(01)90028-4","article-title":"Therapeutic application of thalidomide in multiple myeloma","volume":"28","author":"Kyle","year":"2001","journal-title":"Semin. Oncol."},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0045","doi-asserted-by":"crossref","first-page":"175180","DOI":"10.2169\/internalmedicine.41.175","article-title":"Current therapy of multiple myeloma","volume":"41","author":"Kyle","year":"2002","journal-title":"Intern. Med."},{"issue":"1826","key":"10.2133\/dmpk.DMPK-12-RV-089_bb0050","article-title":"UK Myeloma Forum and the BCSH Haematology\/Oncology Task Forces. Thalidomide in multiple myeloma: current status and future prospects","volume":"120","author":"Cavenagh","year":"2003","journal-title":"Br. J. Haematol."},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0055","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1023\/A:1011141009812","article-title":"Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis: analysis of clinical results and of surrogate angiogenesis markers","volume":"12","author":"Bertolini","year":"2001","journal-title":"Ann. Oncol."},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0060","first-page":"194","article-title":"Management of thalidomide toxicity","volume":"1","author":"Ghobrial","year":"2003","journal-title":"J. Support. Oncol."},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0065","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1021\/ac0203138","article-title":"In vitro biotransformation of (R)- and (S)-thalidomide: application of circular dichroism spectroscopy to the stereochemical characterization of the hydroxylated metabolites","volume":"74","author":"Meyring","year":"2002","journal-title":"Anal. Chem."},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0070","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/(SICI)1099-0461(2000)14:3<140::AID-JBT3>3.0.CO;2-P","article-title":"Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen's disease patients","volume":"14","author":"Teo","year":"2000","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0075","doi-asserted-by":"crossref","first-page":"669","DOI":"10.4161\/cbt.318","article-title":"Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide","volume":"1","author":"Ando","year":"2002","journal-title":"Cancer Biol. Ther."},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0080","first-page":"1964","article-title":"Thalidomide metabolism by the CYP2C subfamily","volume":"8","author":"Ando","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0085","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/sj.thj.6200351","article-title":"S-thalidomide has a greater effect on apoptosis than angiogenesis in a multiple myeloma cell line","volume":"5","author":"Liu","year":"2004","journal-title":"Hematol. J."},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0090","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0021-9673(94)80385-4","article-title":"Investigations on thein vitroracemization of thalidomide by high-performance liquid chromatography","volume":"666","author":"Knoche","year":"1994","journal-title":"J. Chromatogr. A"},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0095","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1248\/cpb.42.1157","article-title":"(S)-form of alpha-methyl-N(alpha)-phthalimidoglutarimide, but not its (R)-form, enhanced phorbol ester-induced tumor necrosis factor-alpha production by human leukemia cell HL-60: implication of optical resolution of thalidomidal effects","volume":"42","author":"Nishimura","year":"1994","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0100","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0009-9236(99)70034-2","article-title":"Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans","volume":"66","author":"Furuta","year":"1999","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0105","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1365-2125.2010.03656.x","article-title":"Potential impact of cytochrome P450 3A5 in human liver on drug interactions with triazoles","volume":"69","author":"Yamazaki","year":"2010","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0110","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1021\/tx900367p","article-title":"Human liver microsomal cytochrome P450 3A enzymes involved in thalidomide 5-hydroxylation and formation of a glutathione conjugate","volume":"23","author":"Chowdhury","year":"2010","journal-title":"Chem. Res. Toxicol."},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0115","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1211\/0022357001774660","article-title":"Intravenous formulations of the enantiomers of thalidomide: pharmacokinetic and initial pharmacodynamic characterization in man","volume":"52","author":"Eriksson","year":"2000","journal-title":"J. Pharm. Pharmacol."},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0120","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/1099-081X(200001)21:1<33::AID-BDD213>3.0.CO;2-R","article-title":"Effect of a high-fat meal on thalidomide pharmacokinetics and the relative bioavailability of oral formulations in healthy men and women","volume":"21","author":"Teo","year":"2000","journal-title":"Biopharm. Drug Dispos."},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0125","doi-asserted-by":"crossref","first-page":"68","DOI":"10.2133\/dmpk.DMPK-11-RV-090","article-title":"In vitro assessment of the allelic variants of cytochrome P450","volume":"27","author":"Hiratsuka","year":"2012","journal-title":"DrugMetab. Pharmacokinet."},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0130","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1124\/dmd.108.021816","article-title":"Defective activity of recombinant cytochromes P450 3A4.2 and 3A4.16 in oxidation of midazolam, nifedipine, and testosterone","volume":"36","author":"Miyazaki","year":"2008","journal-title":"DrugMetab. Dispos."},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0135","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/nbt0897-784","article-title":"Drug metabolism by Escherichia coli expressing human cytochromes P450","volume":"15","author":"Parikh","year":"1997","journal-title":"Nat. Biotechnol."},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0140","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S0006-2952(97)00643-6","article-title":"High catalytic activity of human cytochrome P450 co-expressed with human NADPH-cytochrome P450 reductase in Escherichia coli","volume":"55","author":"Iwata","year":"1998","journal-title":"Biochem. Pharmacol."},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0145","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1248\/bpb.35.317","article-title":"Influence of cytochrome P450 2C19 gene variations on pharmacokinetic parameters of thalidomide in Japanese patients","volume":"35","author":"Matsuzawa","year":"2012","journal-title":"Biol. Pharm. Bull."},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0150","first-page":"651","article-title":"Effect ofCYP2C19gene polymorphism on efficacy of thalidomide-based regimens for the treatment of multiple myeloma","volume":"28","author":"Li","year":"2007","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0155","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1600-0609.2011.01696.x","article-title":"Genetic variations in multiple myeloma II: association with effect of treatment","volume":"88","author":"Vangsted","year":"2012","journal-title":"Eur. J. Haematol."},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0160","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/BF03226408","article-title":"Transport ofthalidomide by the human intestinal caco-2 monolayers","volume":"30","author":"Zhou","year":"2005","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0165","doi-asserted-by":"crossref","first-page":"599606","DOI":"10.1007\/s00280-005-0087-3","article-title":"Thalidomide does not interact with P-glycoprotein","volume":"57","author":"Zimmermann","year":"2006","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0170","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1124\/dmd.108.024679","article-title":"Drug interactions of thalidomide with midazolam and cyclosporine A: heterotropic cooperativity of human cytochrome P450 3A5","volume":"37","author":"Okada","year":"2009","journal-title":"DrugMetab. Dispos."},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0175","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s002800000249","article-title":"In vitro and in vivo kinetic interactions of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenac","volume":"47","author":"Zhou","year":"2001","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0180","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0009-9236(99)70067-6","article-title":"Thalidomide does not alter estrogen-progesterone hormone single dose pharmacokinetics","volume":"65","author":"Scheffler","year":"1999","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0185","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00280-006-0205-x","article-title":"Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmaco-kinetic evaluation","volume":"58","author":"Allegrini","year":"2006","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0190","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1200\/JCO.2010.28.0792","article-title":"Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma","volume":"29","author":"Johnson","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0195","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1186\/1471-2407-10-404","article-title":"No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma","volume":"10","author":"Vangsted","year":"2010","journal-title":"BMC Cancer"},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0200","doi-asserted-by":"crossref","first-page":"43194323","DOI":"10.1200\/JCO.2002.02.116","article-title":"Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma","volume":"20","author":"Rajkumar","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0205","doi-asserted-by":"crossref","first-page":"492494","DOI":"10.1182\/blood.V98.2.492","article-title":"Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase II study of 169 patients","volume":"98","author":"Barlogie","year":"2001","journal-title":"Blood"},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0210","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1056\/NEJM200106213442516","article-title":"Deep venous thrombosis and thalidomide therapy for multiple myeloma","volume":"344","author":"Osman","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0215","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1182\/blood.V98.5.1614","article-title":"Increased risk ofdeep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy","volume":"98","author":"Zangari","year":"2001","journal-title":"Blood"},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0220","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/10245330290020126","article-title":"Thromboembolism in patients on thalidomide for myeloma","volume":"7","author":"Bowcock","year":"2002","journal-title":"Hematology"},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0225","first-page":"1108","article-title":"Thalidomide and thrombosis in patients with multiple myeloma","volume":"86","author":"Camba","year":"2001","journal-title":"Haematologica"},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0230","doi-asserted-by":"crossref","first-page":"4924","DOI":"10.1182\/blood-2008-02-140434","article-title":"Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping","volume":"112","author":"Johnson","year":"2008","journal-title":"Blood"},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0235","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1007\/s00280-006-0203-z","article-title":"Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma","volume":"58","author":"Shiah","year":"2006","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0240","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2165\/00003088-200443050-00004","article-title":"Clinical pharmacokinetics of thalidomide","volume":"43","author":"Teo","year":"2004","journal-title":"Clin. Pharmacokinet."},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0245","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1211\/0022357022241","article-title":"Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis","volume":"55","author":"Eriksson","year":"2003","journal-title":"J. Pharm. Pharmacol."},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0250","first-page":"295","article-title":"Analysis of plasma concentration of thalidomide in Japanese patients of multiple myeloma with renal dysfunction","volume":"50","author":"Arai","year":"2009","journal-title":"Rinsho Ketsueki"},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0255","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1177\/009127009903901108","article-title":"Single-dose oral pharmacokinetics of three formulations of thalidomide in healthy male volunteers","volume":"39","author":"Teo","year":"1999","journal-title":"J. Clin. Pharmacol."},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0260","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1248\/yakushi.128.1449","article-title":"Comparison of dissolution profile and plasma concentration-time profile of the thalidomide formulations made by Japanese","volume":"128","author":"Fujita","year":"2008","journal-title":"Mexican and British companies. Yakugaku Zasshi"},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0265","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1200\/JCO.2010.32.4962","article-title":"Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glyco-protein","volume":"29","author":"Hofmeister","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0270","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00280-003-0753-2","article-title":"Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice: the role of tumour necrosis factor","volume":"53","author":"Chung","year":"2004","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0275","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2174\/138920006776873517","article-title":"Pharmacokinetic mechanisms for reduced toxicity of irinotecan by coadministered thalidomide","volume":"7","author":"Yang","year":"2006","journal-title":"Curr. Drug Metab."},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0280","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00280-006-0249-y","article-title":"Thalidomide and celecoxib as potential modulators of irinotecan's activity in cancer patients","volume":"59","author":"Villalona-Calero","year":"2007","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0285","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1007\/s00280-011-1727-4","article-title":"The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients","volume":"68","author":"Ramirez","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0290","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00280-006-0205-x","article-title":"Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmaco-kinetic evaluation","volume":"58","author":"Allegrini","year":"2006","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0295","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00280-007-0495-7","article-title":"Consequences of increased vascular permeability induced by treatment of mice with 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and thalidomide","volume":"61","author":"Chung","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.2133\/dmpk.DMPK-12-RV-089_bb0300","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s002800100285","article-title":"A difference between the rat and mouse in the pharmacokinetic interaction of 5,6-dimethylxanthenone-4-acetic acid with thalidomide","volume":"47","author":"Zhou","year":"2001","journal-title":"Cancer Chemother. Pharmacol."}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1347436715303761?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1347436715303761?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T21:44:19Z","timestamp":1687815859000},"score":1,"resource":{"primary":{"URL":"http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436715303761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013]]}},"alternative-id":["S1347436715303761"],"URL":"https:\/\/doi.org\/10.2133\/dmpk.dmpk-12-rv-089","relation":{},"ISSN":["1347-4367"],"issn-type":[{"value":"1347-4367","type":"print"}],"subject":[],"published":{"date-parts":[[2013]]}}}